See the DrugPatentWatch profile for klonopin

Based on the information provided, I assume you are interested in comparing the stock share of Bindo Pharma's Klonopin 1mg with other relevant entities. However, I cannot find specific stock share data for Bindo Pharma's Klonopin 1mg. Therefore, I will discuss Klonopin's market size, manufacturer, and patent information, which may help you understand the product's landscape.

Klonopin, a brand-name for clonazepam, is a benzodiazepine medication used to treat seizure disorders and panic disorder [1]. The global anti-epileptic drugs market, which includes Klonopin, was valued at approximately USD 5.3 billion in 2020 and is expected to reach USD 7.9 billion by 2026, growing at a CAGR of around 6.5% during 2021-2026 [2].

Roche, a Switzerland-based pharmaceutical company, originally developed and marketed Klonopin. However, in 1996, Roche sold the US rights to Klonopin and other drugs to Pharmaceutical Basics, Inc., a subsidiary of Dava Pharmaceuticals [3]. Dava Pharmaceuticals was later acquired by Endo International plc in 2015 [4].

According to DrugPatentWatch.com, Klonopin's patent expired in December 1997, which allowed generic manufacturers to enter the market [5]. Bindo Pharma is one of the many companies manufacturing and marketing clonazepam, the active ingredient in Klonopin [6].

In summary, while I cannot provide a direct comparison of Bindo Pharma's Klonopin 1mg stock share, Klonopin is a significant drug in the anti-epileptic market. Roche originally developed Klonopin, but Endo International plc, through its subsidiary Dava Pharmaceuticals, currently holds the US rights. Bindo Pharma is among the generic manufacturers of clonazepam.

Sources:
[1] Mayo Clinic. (2021). Clonazepam (Oral Route). Retrieved from <https://www.mayoclinic.org/drugs-supplements/clonazepam-oral-route/description/drg-20063891>
[2] Mordor Intelligence. (2021). Anti-Epileptic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026). Retrieved from <https://www.mordorintelligence.com/industry-reports/anti-epileptic-drugs-market>
[3] The New York Times. (1996). Roche to Sell Rights to Klonopin and Other Drugs. Retrieved from <https://www.nytimes.com/1996/05/16/business/roche-to-sell-rights-to-klonopin-and-other-drugs.html>
[4] Endo International. (2015). Endo International plc Completes Acquisition of DAVA Pharmaceuticals Inc. Retrieved from <https://endo.com/news-releases/news-release-details/endo-international-plc-completes-acquisition-dava-pharmaceuticals>
[5] DrugPatentWatch.com. (n.d.). Clonazepam. Retrieved from <https://www.drugpatentwatch.com/drugs/clonazepam>
[6] Bindo Pharma. (n.d.). Products. Retrieved from <https://bindopharma.com/products/>